

CURRICULUM VITAE
ROBYN CHUDZINSKI, PHARM.D.

PERSONAL INFORMATION

OFFICE ADDRESS	Beth Israel Deaconess Medical Center Transplant Center 110 Francis Street 7 th Floor Boston, MA 02215
CONTACT INFORMATION	Office phone (617) 632-9841 Cellular phone (646) 342-0927 E-mail rchudzin@bidmc.harvard.edu

EDUCATION

August 1996- May 2000	Doctor of Pharmacy University of Southern California School of Pharmacy Los Angeles, CA
August 1994- May 1996	TAPP Accelerated Program (Trojan Admission to Pre-Pharmacy) University of Southern California Los Angeles, CA

POSTDOCTORAL TRAINING

January 2003- December 2003	Transplant Research Pharmacy Fellowship University of Cincinnati Department of Surgery Division of Transplantation Cincinnati, OH
January 2002- December 2002	Transplant Pharmacy Residency University of Cincinnati Department of Surgery Division of Transplantation Cincinnati, OH

LICENSURE

September 2000- Present	Registered Pharmacist State of Ohio
----------------------------	--

License # 03-1-24355

December 2001-
Present

Registered Pharmacist
State of California
License # 53254

PROFESSIONAL EXPERIENCE

April 2007-
Present

Transplant Clinical Research Administrator
Beth Israel Deaconess Medical Center
Boston, MA

July 2006-
March 2007

Pharmacy Clinical Coordinator
Lahey Clinic
Burlington, MA

July 2004-
July 2006

Transplant Pharmacy Clinical Supervisor
Mount Sinai Hospital
New York, NY

January 2004-
June 2004

Clinical Transplant Pharmacist
University of Cincinnati
Department of Surgery
Division of Transplantation
Cincinnati, OH

October 2000-
December 2001

Clinical/Staff Pharmacist
Christ Hospital
Cincinnati, OH

March 1998-
September 2000

Intern Pharmacist
University of Southern California
University Hospital
Los Angeles, CA

September 1997-
February 1998

Intern Pharmacist
Arcadia Methodist Hospital
Arcadia, CA

PROFESSIONAL MEMBERSHIPS

American Society of Transplantation

American College of Clinical Pharmacists

AWARDS AND HONORS

Young Investigator Award
American Society of Transplantation
American Transplant Congress 2004

TEACHING EXPERIENCE

Pharmacy Resident Preceptor
Transplant Pharmacy

Internal Medicine
Lahey Clinic

Pharmacy Resident Preceptor
Transplant Pharmacy
Mount Sinai Hospital

PA/NP Orientation Program
Transplant Medications
Mount Sinai Hospital

Resident/Fellow Teaching Conference
Pharmacology of Immunosuppressants
Mount Sinai Hospital

Nursing Education
Transplant Medications
Mount Sinai Hospital

Resident/Fellow Teaching Conference
Pharmacology of Immunosuppressants
University of Cincinnati

RESEARCH EXPERIENCE

1. "Pharmacokinetics of Immunosuppressants in Transplant patients who have undergone Gastric Bypass Surgery." American College of Clinical Pharmacy Research Institute Grant. **Co-Investigator**
2. "A Novel Approach for Increasing the Supply of Donor Kidneys for Transplantation: Education Programs as an Adjunct to the Ohio Solid Organ Transplant Consortium Living Donor Kidney Exchange Program." Funded by Second Chance Trust Fund Ohio Department of Health. **Research Coordinator**
3. "An Open-label, concentration controlled, randomized, 12 month study of Prograf, Rapamune, corticosteroids compared to cyclosporine and Rapamune and corticosteroids in high risk renal allograft recipients. Funded by Wyeth Ayerst Pharmaceuticals. **Research Associate**
4. "A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy." Funded by Wyeth Ayerst Pharmaceuticals. **Research Associate**
5. "A Phase II, Open-Label, Multicenter Study to Assess the Pharmacokinetics, Safety and Tolerability in Stable Kidney Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen." Funding by Fujisawa. **Research Associate**
6. "A Phase II, Open-Label, Multicenter Study to Assess the Pharmacokinetics, Safety and Tolerability in Stable Liver Transplant Patients Converted from a Prograf Based Immunosuppression Regimen

- to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen." Funding by Fujisawa. **Research Associate**
7. "A Phase II, Open-Label, Multicenter Study to Assess the Pharmacokinetics, Safety and Tolerability in Stable Heart Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen." Funding by Fujisawa. **Research Associate**
 8. "A prospective, randomized, multicenter trial of early corticosteroid cessation vs. long term maintenance corticosteroid therapy in primary renal allograft recipient's treated with tacrolimus and mycophenolate mofetil." Funded by Fujisawa Pharmaceuticals. **Research Associate**
 9. "A Prospective, pilot study of early corticosteroid cessation with Zenapax, Prograf, Cellcept, and Rapamune in High Immunologic Risk Renal Transplant Recipients" Funded by Roche Laboratories. **Research Associate**
 10. "A Prospective Pilot Study of Corticosteroid Avoidance with Prograf, Cellcept and Rapamune that Avoids Induction Therapy in Renal Transplant Patients" Funded by Wyeth Ayerst Pharmaceuticals. **Research Associate**
 11. "An open-label study to evaluate the safety and efficacy of early (5 day) steroid cessation in de novo renal allograft recipients treated with Simulect induction and Prograf in combination with Rapamune." Funded by Wyeth Ayerst Pharmaceutical. **Research Associate**
 12. "A multicenter, randomized, partially-blinded study of the safety and efficacy of FTY720 combined with corticosteroids and full or reduced dose Neoral in de novo adult renal transplant recipients." Funded Novartis Pharmaceutical Company. **Research Associate**
 13. "Corticosteroid-free, Calcineurin-sparing Immunosuppression Protocol for HLA-Identical Living Donor Renal Transplant Recipients". Funded Roche Laboratories. **Research Associate**
 14. "A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients." Funded by Wyeth Ayerst Pharmaceuticals. **Research Associate**
 15. "Open-Label, Randomized, Prospective Multicenter Study to Compare the Efficacy and Safety among Three Immunosuppressant Treatment Regimens in Patients Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C Infection." Funded by Roche Laboratories. **Research Associate**
 16. "Rapamune Outcomes Assessment Registry." Funded by Wyeth Ayerst Pharmaceutical Company. **Research Associate**
 17. "A Single Center, Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients Utilizing a Tacrolimus/Mycophenolate Mofetil based Maintenance Immunosuppression Protocol." Funded by Fujisawa Healthcare Incorporated. **Research Associate**

18. "A Phase III, randomized, open-label, comparative, multicenter study to assess the safety and efficacy of Prograf/MMF, Modified Release Prograf/MMF and Neoral/MMF in de novo kidney transplant recipients'. Funding by Fujisawa Healthcare Incorporated. **Research Associate**
19. "FK 778 De Novo Renal Transplant Study". Funding by Fujisawa Healthcare Incorporated. **Research Associate**
20. "Randomized, prospective, Phase II Study comparing Thymoglobulin in a rapid discontinuation of corticosteroids protocols with standard corticosteroid therapy in living donor renal transplantation using mycophenolate mofetil and tacrolimus maintenance therapy." Funding by SangStat Medical Corporation. **Research Associate**
21. "Evaluation of Immune Globulin Intravenous, (Human), 10%, Manufactured By Chromatography Process (IGIV-C, 10%), As An Agent To Reduce Anti-HLA Antibodies And Improve Transplantation Results In Cross Match Positive Living Donor Kidney Allograft Recipients" Funding by NIH. **Research Associate**
22. "Extension: A Prospective Pilot Study of Corticosteroid Avoidance with Prograf, Cellcept and Rapamune that Avoids Induction Therapy in Renal Transplant Patients" Funded by Wyeth Ayerst Pharmaceuticals. **Research Associate**
23. "Clinical, Immunologic, and Pharmacologic Consequences of Kidney and Liver Transplantation in People with HIV Infection." Funding by National Institute of Health. **Research Associate**

PUBLICATIONS

Articles

1. **Boardman R**, Trofe J, Alloway R, Rogers C, Roy-Chaudhury P, Cardi M, Safdar S, Groene B, Buell J, Hanaway M, Thomas M, Alexander W, Munda R, Woodle ES. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis. *Transplant Proc.* 2005 Mar;37(2):817-8.
2. **Boardman RE**, Alloway RR, Alexander JW, Buell JF, Cardi M, First MR, Hanaway MT, Munda R, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES. African American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. *Transplant Proc.* 2005 Mar;37(2):814-6.
3. **Boardman RE**, Alloway RR, Alexander JW, Buell JF, Cardi M, First MR, Hanaway MJ, Munda R, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES. African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. *Am J Transplant.* 2005 Feb;5(2):356-65.
4. Rogers CC, Alloway RR, Buell JF, **Boardman R**, Alexander JW, Cardi M, Roy-Chaudhury P, First MR, Succop P, Munda R, Woodle ES. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. *Transplantation.* 2005 Jul 15;80(1):26-33.

5. Rogers CC, Alloway RR, **Boardman R**, Trofe J, Hanaway MJ, Alexander JW, Roy-Chaudhury P, Buell JF, Thomas M, Susskind B, Woodle ES. Global cardiovascular risk under early corticosteroid cessation decreases progressively in the first year following renal transplantation. *Transplant Proc.* 2005 Mar;37(2):812-3.
6. Woodle ES, Susskind B, Alloway RR, Hanaway MJ, Thomas M, Buell J, Alexander JW, Roy-Chaudhury P, Succop P, Cardi M, **Boardman R**, Rogers C. Histocompatibility testing predicts acute rejection risk in early corticosteroid withdrawal regimens. *Transplant Proc.* 2005 Mar;37(2):809-11.
7. Alloway RR, Hanaway MJ, Trofe J, **Boardman R**, Rogers CC, Hanaway MJ, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. *Transplant Proc.* 2005 Mar;37(2):802-3.
8. Rogers CC, Hanaway M, Alloway RR, Alexander JW, **Boardman RE**, Trofe J, Gupta M, Merchen T, Buell JF, Cardi M, Roy-Chaudhury P, Succop P, Woodle ES. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. *Transplant Proc.* 2005 Mar;37(2):795-7.
9. Woodle ES, **Boardman R**, Bohnengel A, Downing K. Influence of educational programs on perceived barriers toward living donor kidney exchange programs. *Transplant Proc.* 2005 Mar;37(2):602-4.
10. Woodle ES, Bohnengel A, **Boardman R**, Downing K; Ohio Solid Organ Transplant Consortium Kidney Committee. Kidney exchange programs: attitudes of transplant team members toward living donation and kidney exchanges. *Transplant Proc.* 2005 Mar;37(2):600-1.
11. DeSalvo D, Roy-Chaudhury P, Peddi R, Merchen T, Konijetti K, Gupta M, Boardman R, Rogers C, Buell J, Hanaway M, Broderick J, Smith R, Woodle ES. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. *Transplantation.* 2004 Feb 15;77(3):466-9.

Abstracts

1. Ruxandra Necula, **Robyn Boardman**, Sukru Emre, Thomas Schiano, Nanda Kerkar, Allen Ahdoot. Retrospective review of the immunosuppressive agent sirolimus in liver transplantation. 40th ASHP Midyear Clinical Meeting and Exhibition 2005; Las Vegas, NV
2. **Boardman RE**, Gross TG, Hanaway MJ, First MR, Trofe J, Alloway RR, Beebe TM, Woodle ES. De novo ovarian cancer post solid organ transplantation. *American Journal of Transplantation* 2003; 3(suppl 5): 188.
3. **Boardman RE**, Alloway, RR, Rogers, C, Clippard, M, Gupta M, Merchen T, Metze T, Susskind B, Trofe J, Peddi V, Woodle, ES. African American renal transplant recipients: Experience with early corticosteroid cessation under modern immunosuppression. *American Journal of Transplantation* 2003; 3(suppl 5): 175.

4. Clippard M, Alloway RR, **Boardman RE**, Hanaway M, Buell JF, Trofe J, Alexander JW, Metze T, Cardi M, Roy-Chaudhury P, Gupta M, Munda R, Woodle ES. Delayed graft function: Implications for steroid elimination in kidney transplantation. *American Journal of Transplantation* 2003; 3(suppl 5): 360.
5. Rogers C, Alloway R, **Boardman RE**, Trofe J, Hanaway M, Alexander J, Peddi R, Roy-Chaudhury P, Cardi M, Susskind B, Woodle ES. Cardiovascular risk alterations with early corticosteroid cessation under modern immunosuppression: Objective assessment by Framingham risk analysis. *American Journal of Transplantation* 2003; 3 (suppl 5): 213.
6. Trofe J, Gordon J, Roy-Chaudhury P, Mutema G, Cavallo T, Buell JF, Alloway RR, Safdar S, Cardi M, Hanaway MJ, Austin J, Goel S, Huang S, Peddi VR, C Rogers, **Boardman RE**, Munda R, Alexander JW, Khalili K, Woodle ES. Correlation of BK viral load monitoring and host immune responses in post-transplant polyomavirus nephropathy. *American Journal of Transplantation* 2003; 3 (suppl 5): 370.
7. Trofe J, Roy-Chaudhury P, Gordon J, Mutema G, Cavallo T, Cardi M, Austin J, Goel S, Rogers C, **Boardman RE**, Clippard M, Alloway RR, Alexander JW, Metze T, Goodman H, Hanaway MJ, Munda R, Buell JF, Peddi VR, Safdar S, Huang S, Fidler J, Khalili K, Woodle ES. Early steroid cessation/avoidance regimens are associated with a lower incidence of Polyoma virus nephropathy compared to steroid based immunosuppression in kidney transplant recipients. *American Journal of Transplantation* 2003; 3 (suppl 5): 371.
8. Chudzinski AP, **Boardman RE**, Gupta M, Hanaway MJ, Merchen T, Clippard M, Woodle ES, Buell JF. Long-term analysis of graft function in right laparoscopic donor nephrectomy: A case controlled series. *American Journal of Transplantation* 2003; 3 (suppl 5): 490.
9. Chudzinski AP, **Boardman RE**, Gupta M, Hanaway MJ, Merchen TD, Clippard M, Buell JF, Woodle ES. Long-term analysis of right laparoscopic donor nephrectomy graft function: A case controlled series. *Central Surgical Association* 2003, Ontario, Canada
10. DeSalvo D, Roy-Chaudhury P, Merchen T, Konijetti K, Gupta M, **Boardman RE**, Rogers C, Hanaway M, Buell J, Konoplev K, Smith R, Woodle ES, Peddi R. West Nile virus encephalitis in organ transplant recipients: Another high-risk group for Meningoencephalitis and death? *American Journal of Transplantation* 2003; 3 (suppl 5): 300.

PROFESSIONAL PRESENTATIONS

1. "De Novo Breast Cancer Post Solid Organ Transplantation" *American Transplantation Congress* 2004 Oral Presentation
2. "Early Steroid Withdrawal Does Not Increase Risk for Recurrent Focal Segmental Glomerulosclerosis." *American Transplantation Congress* 2004 Oral Presentation
3. "Bone Pain in Renal Transplantation: Does Sirolimus Play a Role?" *American Transplantation Congress* 2004 Oral Presentation
4. "De Novo Ovarian Cancer Post Solid Organ Transplantation." *American Transplantation Congress* 2003 Oral Presentation

5. "African American Renal Transplant Recipients: Experience with Early Corticosteroid Cessation Under Modern Immunosuppression." American Transplantation Congress 2003 Oral Presentation
6. "Corticosteroid Elimination in Solid Organ Transplantation" American College of Clinical Pharmacy Business and Networking Meeting 2003
7. "US Multi-center Randomized, Double Blind Placebo-Controlled Early CSWD Trial Under Thymoglobulin or Anti-IL-2R Ab Induction, Tacrolimus, and MMF Therapy." International Transplant Nursing Society 2003
8. "A Multi-center, Open Label Pilot Study of Early (4 Day) Corticosteroid Cessation in De Novo Renal Transplant Recipients Under Simulect, Tacrolimus, and Sirolimus Therapy: Interim Analysis." International Transplant Nursing Society 2003
6. "Steroid Withdrawal in Renal Transplantation: Management of Steroid Related Side Effects." International Transplant Nursing Society 2003

INVITED PRESENTATIONS

"Pharmacology of Immunosuppressants" Roche Laboratories

FUNDING

"Pharmacokinetics of Immunosuppressants in Transplant Patients Who Have Undergone Gastric Bypass Surgery." American College of Clinical Pharmacy Research Institute Grant. Co-investigator **\$27,500**

EDITORIAL REVIEWS

1. The Annals of Pharmacotherapy; September 2002.
2. Progress in Transplantation; October 2003.
3. Alimentary Pharmacology & Therapeutics; December 2004

ADVISORY BOARD

1. Roche Transplant Pharmacy Advisory Board Meeting
February 2005
2. Enzon Pharmaceuticals- Fungal Therapy Advisory Board
November 2003
3. Enzon Pharmaceuticals- Fungal Therapy Advisory Board
August 2003